Celltech may abandon launch of treatment for Crohn's disease
Wednesday 31 July 2002
Celltech shareholders suffered a double blow yesterday when the company said it was considering abandoning the launch of its most advanced new drug and would halve its US salesforce.
The drug, Humicade, was being tested as a treatment for Crohn's disease, which causes inflammation of the gut, and had been expected on the market next year. But clinical trials failed to show it was effective.
The data suggests Humicade could still be useful in the treatment of acute forms of the disease, but Celltech said it would talk to US and European regulators to establish if it was likely to gain approval. Analysts predicted that, if the regulator said it would need additional trials to be carried out, the company would drop the product and concentrate development work on a second drug, CDP 870. This is a more effective product treating the same diseases as Humicade.
The company said it is to set up a specialist gastroenterology salesforce in advance of the launch of CDP 870, and that it had paid $6m to the US giant Pharmacia to license Dipentum, a treatment for an inflammatory bowel disorder which had sales of $11m in 2001.
But it is cutting its losses on Metadate, a once promising treatment for hyperactive children. The disappointing sales mean it can no longer sustain a US salesforce of 350, and this will be slashed to 170. The drug will no longer be actively marketed, and sales are unlikely to grow beyond the current $25m a year.
Metadate has struggled in the cut-throat US market for treating hyperactive children. Johnson & Johnson's Concerta has a 25 per cent market share and Shire Pharmaceuticals, the UK's number three drug company, will say later this week that it has won a 26 per cent share with its product Adderall.
Celltech shares fell more than 7 per cent to 397p.
- 1 Israel-Gaza conflict: 'When Genocide is Permissible' article removed from The Times of Israel website
- 2 Pope Francis issues top 10 tips for happiness
- 3 Disney heiress Abigail disowns her share of family profits in West Bank company
- 4 The secret report that helps Israel hide facts
- 5 Israel's propaganda machine is finally starting to misfire
Lost portraits of the Somme: 100 images of Tommies posing before they went over the top. Now can you help to identify them?
Israel-Gaza conflict: 'When Genocide is Permissible' article removed from The Times of Israel website
Mystery of the Siberian holes at the end of the world 'solved': Scientists offer explanation
Pope Francis issues top 10 tips for happiness
Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
Land for gas: Merkel and Putin discussed secret deal could end Ukraine crisis
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Boozy, ignorant, intolerant, but very polite – Britain as others see us
A new Russian revolution: The cracks are starting to appear in Putin’s Kremlin power bloc
- < Previous
- Next >
iJobs Money & Business
£300 - £350 per day: Orgtel: Financial Analyst, Forecasting, Halifax, Banking,...
£500 per day: Orgtel: Business Architect - Banking - Bristol - £500 per day A...
£200 - £500 per day + competitive: Orgtel: I am currently working on a large p...
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...